Inactive Instrument

Perrigo Company PLC Stock TEL AVIV STOCK EXCHANGE

Equities

IE00BGH1M568

Pharmaceuticals

Sales 2024 * 4.66B 1,771B Sales 2025 * 4.86B 1,849B Capitalization 4.23B 1,609B
Net income 2024 * -51M -19.39B Net income 2025 * 101M 38.4B EV / Sales 2024 * 1.59 x
Net Debt 2024 * 3.18B 1,210B Net Debt 2025 * 3.01B 1,143B EV / Sales 2025 * 1.49 x
P/E ratio 2024 *
-83.7 x
P/E ratio 2025 *
55.8 x
Employees -
Yield 2024 *
3.53%
Yield 2025 *
3.75%
Free-Float 99.69%
More Fundamentals * Assessed data
Dynamic Chart
Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million MT
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc for approximately ?280 million. CI
Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost MT
Multiple CVS Caremark Plans Reportedly to Cover Perrigo's Opill at No Cost MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading MT
Perrigo Shares Rise After Wisconsin Governor Makes Birth Control Pill Free for Medicaid Members MT
Transcript : Perrigo Company plc Presents at UBS Global Consumer and Retail Conference 2024, Mar-13-2024 04:00 PM
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors CI
Perrigo Company plc Commences Shipments of Opill to Retailers Nationwide, Empowering Millions to Enter A New Era of Reproductive Health Access in the United States CI
Perrigo Co Insider Bought Shares Worth $252,168, According to a Recent SEC Filing MT
JPMorgan Cuts Price Target on Perrigo to $41 From $48, Maintains Overweight Rating MT
Perrigo Company plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 55 23-06-29
Director of Finance/CFO 49 22-05-15
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 55 20-12-14
Director/Board Member 68 17-02-05
Director/Board Member 67 17-02-05
More insiders
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.
Calendar
More about the company